The Ongoing Research on Bevacizumab in Non-Small Cell Lung Cancer

Advancements in cancer care focus on precise detection of measurable residual disease, enhancing monitoring and relapse prediction through innovative technologies and AI integration.

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

Taletrectinib emerges as a groundbreaking treatment for ROS1-mutant NSCLC, offering hope with its CNS activity and lower neurological side effects.

In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.

Hyung Kim, MD, discussed the PROBE trial, a trial in progress, for patients with advanced kidney cancer.

Taletrectinib gains FDA approval as a groundbreaking treatment for ROS1-positive non-small cell lung cancer, offering hope for patients with CNS involvement.